Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by ameda33on Jan 28, 2021 12:25pm

194 Views

Post# 32410210

Enhancement of Strength

Sponsored Post:

Have you ever heard of the potentially game changing innovation in the green leaf industry? You’ve come across this for a reason.

The escalating legalization of green leaf in several countries for medical purposes might potentially strengthen the market during the forecast period. It could provide relief from vomiting, chronic pain, and sleep difficulties are likely to enhance the clamor for medical green leaf, which might potentially boost the medical industry growth in the coming period.

Researchers seem to be progressively studying the chemicals in green leaf to discover new applications. Check disclaimer on profile and landing page.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market